» Articles » PMID: 35766025

Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B

Abstract

Background: CD (cluster of differentiation) 4 T-cell responses to APOB (apolipoprotein B) are well characterized in atherosclerotic mice and detectable in humans. CD4 T cells recognize antigenic peptides displayed on highly polymorphic HLA (human leukocyte antigen)-II. Immunogenicity of individual APOB peptides is largely unknown in humans. Only 1 HLA-II-restricted epitope was validated using the DRB1*07:01-APOB tetramer. We hypothesized that human APOB may contain discrete immunodominant CD4 T-cell epitopes that trigger atherosclerosis-related autoimmune responses in donors with diverse HLA alleles.

Methods: We selected 20 APOB-derived peptides (APOB) from an in silico screen and experimentally validated binding to the most commonly occurring human HLA-II alleles. We optimized a restimulation-based workflow to evaluate antigenicity of multiple candidate peptides in HLA-typed donors. This included activation-induced marker assay, intracellular cytokine staining, IFNγ (interferon gamma) enzyme-linked immunospot and cytometric bead array. High-throughput sequencing revealed TCR (T-cell receptor) clonalities of APOB-reactive CD4 T cells.

Results: Using stringent positive, negative, and crossover stimulation controls, we confirmed specificity of expansion-based protocols to detect CD4 T cytokine responses to the APOB pool. Ex vivo assessment of AIMCD4 T cells revealed a statistically significant autoimmune response to APOB but not to a ubiquitously expressed negative control protein, actin. Resolution of CD4 T responses to the level of individual peptides using IFNγ enzyme-linked immunospot led to the discovery of 6 immunodominant epitopes (APOB) that triggered robust CD4 T activation in most donors. APOB-specific responding CD4 T cells were enriched in unique expanded TCR clonotypes and preferentially expressed memory markers. Cytometric bead array analysis detected APOB-induced secretion of both proinflammatory and regulatory cytokines. In clinical samples from patients with angiographically verified coronary artery disease, APOB stimulation induced higher activation and memory phenotypes and augmented secretion of proinflammatory cytokines TNF (tumor necrosis factor) and IFNγ, compared with patients with low coronary artery disease.

Conclusions: Using 3 cohorts, each with ≈20 donors, we discovered and validated 6 immunodominant, HLA-II-restricted APOB epitopes. The immune response to these APOB epitopes correlated with coronary artery disease severity.

Citing Articles

Legumain deficiency halts atherogenesis by modulating T cell receptor signaling.

Xiang X, Zhang F, Nie L, Guo X, Qin M, Chen J Aging Cell. 2024; 24(2):e14391.

PMID: 39473192 PMC: 11822642. DOI: 10.1111/acel.14391.


Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization.

Gerdes N, Klingenberg R Front Cardiovasc Med. 2024; 11:1448664.

PMID: 39211769 PMC: 11357920. DOI: 10.3389/fcvm.2024.1448664.


Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells.

Depuydt M, Schaftenaar F, Prange K, Boltjes A, Hemme E, Delfos L Nat Cardiovasc Res. 2024; 2(2):112-125.

PMID: 38665903 PMC: 11041750. DOI: 10.1038/s44161-022-00208-4.


Identification of apolipoprotein B-reactive CDR3 motifs allows tracking of atherosclerosis-related memory CD4T cells in multiple donors.

Roy P, Suthahar S, Makings J, Ley K Front Immunol. 2024; 15:1302031.

PMID: 38571941 PMC: 10988780. DOI: 10.3389/fimmu.2024.1302031.


Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities.

Stroope C, Nettersheim F, Coon B, Finney A, Schwartz M, Ley K Nat Metab. 2024; 6(4):617-638.

PMID: 38532071 PMC: 11055680. DOI: 10.1038/s42255-024-01015-w.


References
1.
Hardy M, Goel G, Russell A, Chen Yi Mei S, Brown G, Wang S . A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. Front Immunol. 2021; 12:661622. PMC: 8171185. DOI: 10.3389/fimmu.2021.661622. View

2.
Marchini T, Hansen S, Wolf D . ApoB-Specific CD4 T Cells in Mouse and Human Atherosclerosis. Cells. 2021; 10(2). PMC: 7922692. DOI: 10.3390/cells10020446. View

3.
Arlehamn C, Pham J, Alcalay R, Frazier A, Shorr E, Carpenter C . Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. J Immunol. 2019; 203(1):84-92. PMC: 6581570. DOI: 10.4049/jimmunol.1801506. View

4.
Malhotra D, Linehan J, Dileepan T, Lee Y, Purtha W, Lu J . Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns. Nat Immunol. 2016; 17(2):187-95. PMC: 4718891. DOI: 10.1038/ni.3327. View

5.
Nilsson J, Bjorkbacka H, Fredrikson G . Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr Opin Lipidol. 2012; 23(5):422-8. DOI: 10.1097/MOL.0b013e328356ec7c. View